FASN and metabolic syndrome: In addition, we found that co-treatment with simvastatin improved olanzapine-induced dyslipidemia, inhibited transcriptional levels of Hmgcr, Srebp1 and Fasn, and reversed the decreased levels of UCP1 and PGC-1α in BAT by olanzapine treatment.